Verenigde Staten - Engels - NLM (National Library of Medicine)

american health packaging - folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8) - folic acid is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood. folic acid is contraindicated in patients who have shown previous intolerance to the drug.

Verenigde Staten - Engels - NLM (National Library of Medicine)

rising pharma holdings, inc. - folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8) - folic acid, usp is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid, usp (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood. folic acid, usp is contraindicated in patients who have shown previous intolerance to the drug.

Verenigde Staten - Engels - NLM (National Library of Medicine)

laboratorios h.g. c.a. - benzoic acid 6.0 g, salycylic acid 2.5 g, sulfur 4.6 g - against eczema, pimples and other skin conditions skin treatment against eczema, pimples and other skin conditions. treatment of dermatophyte infections. symptoms persist

Nieuw-Zeeland - Engels - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - benzoic acid 2.01%{relative}; chlorhexidine gluconate 0.5%{relative}; resorcinol 8%{relative}; salicylic acid 1.01%{relative};  ; undecenoic acid monoethanolamide 5%{relative} - topical solution - active: benzoic acid 2.01%{relative} chlorhexidine gluconate 0.5%{relative} resorcinol 8%{relative} salicylic acid 1.01%{relative}   undecenoic acid monoethanolamide 5%{relative} excipient: acetone butyl hydroxybenzoate ethanol purified water

Verenigde Staten - Engels - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - bupropion hydrochloride (unii: zg7e5poy8o) (bupropion - unii:01zg3tpx31) - bupropion hydrochloride 100 mg - bupropion hydrochloride extended-release tablets (sr) are indicated for the treatment of major depressive disorder (mdd), as defined by the diagnostic and statistical manual (dsm) . the efficacy of bupropion in the treatment of a major depressive episode was established in two 4-week controlled inpatient trials and one 6-week controlled outpatient trial of adult subjects with mdd [see clinical studies (14)] . the efficacy of bupropion hydrochloride extended-release tablets (sr) in maintaining an antidepressant response for up to 44 weeks following 8 weeks of acute treatment was demonstrated in a placebo-controlled trial [see clinical studies (14)] . data from epidemiological studies of pregnant women exposed to bupropion in the first trimester indicate no increased risk of congenital malformations overall. all pregnancies, regardless of drug exposure, have a background rate of 2% to 4% for major malformations, and 15% to 20% for pregnancy loss. no clear evidence of teratogenic activity was found in reproducti

Verenigde Staten - Engels - NLM (National Library of Medicine)

ar scientific, inc. - sulfamethoxazole (unii: je42381tnv) (sulfamethoxazole - unii:je42381tnv) - sulfamethoxazole 800 mg

Verenigde Staten - Engels - NLM (National Library of Medicine)

hospira, inc. - lidocaine hydrochloride (unii: v13007z41a) (lidocaine - unii:98pi200987), epinephrine (unii: ykh834o4bh) (epinephrine - unii:ykh834o4bh) - lidocaine hydrochloride anhydrous 15 mg in 1 ml - lidocaine hydrochloride and epinephrine injection, usp is indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection, by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed. lidocaine hcl is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type.

Verenigde Staten - Engels - NLM (National Library of Medicine)

rising health, llc - sulfamethoxazole (unii: je42381tnv) (sulfamethoxazole - unii:je42381tnv), trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - sulfamethoxazole 400 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. for the treatment of urinary tract infections due to susceptible strains of the following organisms: escherichia coli, klebsiella species, enterobacter species, morganella morganii, proteus mirabilis and proteus vulgaris. it is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. for the treatment of acute otitis media in pe

Verenigde Staten - Engels - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - sulfamethoxazole (unii: je42381tnv) (sulfamethoxazole - unii:je42381tnv), trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - sulfamethoxazole 400 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. urinary tract infections for the treatment of urinary tract infections due to susceptible strains of the following organisms: escherichia coli , klebsiella species, enterobacter species, morganella morganii , proteus mirabilis and proteus vulgaris . it is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. acute otitis media

Verenigde Staten - Engels - NLM (National Library of Medicine)

avkare - sulfamethoxazole (unii: je42381tnv) (sulfamethoxazole - unii:je42381tnv), trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - sulfamethoxazole 400 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets, usp and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. urinary tract infections: for the treatment of urinary tract infections due to susceptible strains of the following organisms: escherichia coli , klebsiella species, enterobacter species, morganella morganii , proteus mirabilis and proteus vulgaris . it is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. acute otitis media: for the treatment of acute otitis media in pediatric patients due to susceptible strains of streptococcus pneumoniae or haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. to date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim in pediatric patients under two years of age. sulfamethoxazole and trimethoprim is not indicated for prophylactic or prolonged administration in otitis media at any age. acute exacerbations of chronic bronchitis in adults: for the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of streptococcus pneumoniae or haemophilus influenzae when a physician deems that sulfamethoxazole and trimethoprim could offer some advantage over the use of a single antimicrobial agent. shigellosis: for the treatment of enteritis caused by susceptible strains of shigella flexneri and shigella sonnei when antibacterial therapy is indicated. pneumocystis jiroveci pneumonia: for the treatment of documented pneumocystis jiroveci pneumonia and for prophylaxis against p. jiroveci pneumonia in individuals who are immunosuppressed and considered to be at an increased risk of developing p. jiroveci pneumonia. traveler’s diarrhea in adults: for the treatment of traveler’s diarrhea due to susceptible strains of enterotoxigenic e. coli . sulfamethoxazole and trimethoprim is contraindicated in patients with a known hypersensitivity to trimethoprim, usp or sulfonamides, in patients with a history of drug-induced immune thrombocytopenia with use of trimethoprim, usp and/or sulfonamides, and in patients with documented megaloblastic anemia due to folate deficiency. sulfamethoxazole and trimethoprim is contraindicated in pediatric patients less than 2 months of age. sulfamethoxazole and trimethoprim is also contraindicated in patients with marked hepatic damage or with severe renal insufficiency when renal function status cannot be monitored.